This is also true of the other Bcr-Abl kinase inhibitors such as nilotinib and dasatinib, which have been shown to be ineffective in CML harboring BCR-ABL-T315I mutation, thus, rendering the therapeutic promise of IM and these other Bcr-Abl kinase inhibitors elusive in CML. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.